Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Zofran Odt, Zuplenz. Every FDA application for this active ingredient: 2 branded and 12 generic.
As of Nov 14, 2026, FDA lists 14 applications for Ondansetron (sold as Zofran Odt, Zuplenz), first approved Jan 27, 1999, with 0 new uses approved and 0 published complete response letters.
First approved: Jan 27, 1999
Applications: 14
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $99.1M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
OndansetronA drug with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. · Maruishi Pharmaceutical Co., Ltd. · Feb 25, 2022
Clinical Trials
100 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Sandoz
Teva
Sun Pharm Inds
Aurobindo Pharma